company background image
PNV logo

PolyNovo ASX:PNV Voorraadrapport

Laatste prijs

AU$2.07

Marktkapitalisatie

AU$1.4b

7D

2.5%

1Y

50.5%

Bijgewerkt

08 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

PNV Overzicht aandelen

PolyNovo Limited ontwerpt, produceert en verkoopt biologisch afbreekbare medische hulpmiddelen in de Verenigde Staten, Australië, Nieuw-Zeeland en internationaal.

PolyNovo Limited Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor PolyNovo
Historische aandelenkoersen
Huidige aandelenkoersAU$2.07
52 Week HoogtepuntAU$2.78
52 Week LaagAU$1.30
Bèta1.72
11 maand verandering-14.81%
3 maanden verandering-14.81%
1 Jaar Verandering50.55%
33 jaar verandering37.09%
5 jaar verandering-6.33%
Verandering sinds IPO935.00%

Recent nieuws en updates

Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Oct 10
Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Recent updates

Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Oct 10
Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital

Aug 28
PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Aug 06
PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

May 08
PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

When Should You Buy PolyNovo Limited (ASX:PNV)?

Feb 28
When Should You Buy PolyNovo Limited (ASX:PNV)?

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Feb 02
Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 08
PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Sep 22
Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

When Should You Buy PolyNovo Limited (ASX:PNV)?

Jun 26
When Should You Buy PolyNovo Limited (ASX:PNV)?

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

May 30
Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Apr 18
Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Mar 23
Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Feb 05
Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Returns At PolyNovo (ASX:PNV) Are On The Way Up

Nov 16
Returns At PolyNovo (ASX:PNV) Are On The Way Up

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01
PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Jul 29
What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Jun 15
PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

May 16
Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Apr 28
We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Mar 07
There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

Dec 13
Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

Oct 19
PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

May 08
Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat

Feb 27
News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat

Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts

Feb 25
Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts

Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?

Feb 17
Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?

Rendement voor aandeelhouders

PNVAU Medical EquipmentAU Markt
7D2.5%2.0%0.7%
1Y50.5%13.8%16.7%

Rendement versus industrie: PNV overtrof de Australian Medical Equipment industrie, die het afgelopen jaar een rendement 13.8 % opleverde.

Rendement versus markt: PNV overtrof de Australian markt, die het afgelopen jaar een rendement opleverde van 16.7 %.

Prijsvolatiliteit

Is PNV's price volatile compared to industry and market?
PNV volatility
PNV Average Weekly Movement6.1%
Medical Equipment Industry Average Movement9.8%
Market Average Movement8.5%
10% most volatile stocks in AU Market17.2%
10% least volatile stocks in AU Market3.5%

Stabiele aandelenkoers: PNV heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van PNV is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
1998254Swami Raotepolynovo.com

PolyNovo Limited ontwerpt, produceert en verkoopt biologisch afbreekbare medische hulpmiddelen in de Verenigde Staten, Australië, Nieuw-Zeeland en internationaal. Het bedrijf biedt NovoSorb Biodegradable Temporising Matrix, een huidsteiger voor de regeneratie van de lederhuid wanneer deze verloren is gegaan door een uitgebreide operatie, trauma of brandwond. Het ontwikkelt ook hernia-instrumenten voor herniaherstel en oplossingen voor ventrale hernia en complexe buikwandreconstructie; NovoSorb Dermal Beta Cell, een nieuwe intracutane ectopische pancreas voor de behandeling van diabetes type 1; NovoSorb MTX voor transplantatie in één stadium bij brandwonden, chronische en chirurgische wonden; en producten voor plastische en reconstructieve hulpmiddelen.

PolyNovo Limited Samenvatting

Hoe verhouden de winst en inkomsten van PolyNovo zich tot de beurswaarde?
PNV fundamentele statistieken
MarktkapitalisatieAU$1.41b
Inkomsten(TTM)AU$5.26m
Inkomsten(TTM)AU$103.23m

271.8x

Koers/Winstverhouding

13.9x

P/S-verhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PNV resultatenrekening (TTM)
InkomstenAU$103.23m
Kosten van inkomstenAU$16.41m
BrutowinstAU$86.82m
Overige uitgavenAU$81.56m
InkomstenAU$5.26m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)0.0076
Brutomarge84.11%
Nettowinstmarge5.10%
Schuld/Eigen Vermogen Verhouding3.6%

Hoe presteerde PNV op de lange termijn?

Bekijk historische prestaties en vergelijking